Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- CheckyesterdayChange Detected- Revision updated from v3.3.3 to v3.3.4 in the page header. This is a metadata change and does not modify the study details, eligibility criteria, or locations.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedThe study Locations list was updated to add new sites across the U.S., Argentina, Australia, Italy, China, India, Spain, and other regions, and several previously listed locations were removed.SummaryDifference2%

- Check51 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page, with no changes to the study details or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedMinor metadata updates to the PubMed publications attribution and revision label in the study details (v3.3.1), replacing the previous PubMed attribution and revision (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedDeleted the government funding/operating status notice from the page, removing a generic informational banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check79 days agoChange DetectedThe changes appear to be minor UI/layout adjustments between versions, with no alterations to core study details or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.